HK1052351B - Benzothiazolyl ppar-gamma modulators - Google Patents
Benzothiazolyl ppar-gamma modulators Download PDFInfo
- Publication number
- HK1052351B HK1052351B HK03104574.3A HK03104574A HK1052351B HK 1052351 B HK1052351 B HK 1052351B HK 03104574 A HK03104574 A HK 03104574A HK 1052351 B HK1052351 B HK 1052351B
- Authority
- HK
- Hong Kong
- Prior art keywords
- chloro
- nmr
- dmso
- compound
- dichloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Quinoline Compounds (AREA)
- Holo Graphy (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21481000P | 2000-06-28 | 2000-06-28 | |
| US60/214,810 | 2000-06-28 | ||
| PCT/US2001/020756 WO2002000633A1 (en) | 2000-06-28 | 2001-06-27 | Quinolinyl and benzothiazolyl ppar-gamma modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HK1052351A1 HK1052351A1 (en) | 2003-09-11 |
| HK1052351B true HK1052351B (en) | 2006-11-03 |
Family
ID=22800496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK03104574.3A HK1052351B (en) | 2000-06-28 | 2001-06-27 | Benzothiazolyl ppar-gamma modulators |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1296967B1 (enExample) |
| JP (1) | JP4515026B2 (enExample) |
| KR (1) | KR100771286B1 (enExample) |
| CN (1) | CN1243741C (enExample) |
| AT (1) | ATE327984T1 (enExample) |
| AU (2) | AU2001271637B2 (enExample) |
| BR (1) | BRPI0112115B8 (enExample) |
| CA (1) | CA2412723C (enExample) |
| CY (1) | CY1105126T1 (enExample) |
| CZ (1) | CZ302982B6 (enExample) |
| DE (1) | DE60120163T2 (enExample) |
| DK (1) | DK1296967T3 (enExample) |
| EA (1) | EA005976B1 (enExample) |
| ES (1) | ES2265435T3 (enExample) |
| HK (1) | HK1052351B (enExample) |
| HU (1) | HUP0301482A3 (enExample) |
| IL (2) | IL153461A0 (enExample) |
| MX (1) | MXPA02012708A (enExample) |
| NO (1) | NO325448B1 (enExample) |
| NZ (1) | NZ523229A (enExample) |
| PL (1) | PL214670B1 (enExample) |
| PT (1) | PT1296967E (enExample) |
| SK (1) | SK288236B6 (enExample) |
| WO (1) | WO2002000633A1 (enExample) |
| ZA (1) | ZA200210283B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| NZ531917A (en) | 2001-09-14 | 2006-01-27 | Japan Tobacco Inc | Linked biaryl compounds |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| NZ566263A (en) | 2002-05-24 | 2009-09-25 | Millennium Pharm Inc | CCR9 inhibitors and methods of use thereof |
| US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
| ATE363470T1 (de) | 2002-11-18 | 2007-06-15 | Chemocentryx Inc | Arylsulfonamide |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| KR101106631B1 (ko) | 2003-02-13 | 2012-01-20 | 웰스태트 테러퓨틱스 코포레이션 | 대사 질환의 치료용 화합물 |
| KR20060025132A (ko) * | 2003-04-11 | 2006-03-20 | 더 유니버시티 오브 테네시 리서치 파운데이션 | 리소포스파티드산 유사체 및 신생내막 형성의 저해 |
| JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| EP1630152A4 (en) * | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONDENSED CYCLIC COMPOUND |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| EP1786782B1 (en) | 2004-08-12 | 2010-03-31 | Amgen Inc. | Bisaryl-sulfonamides |
| KR101346902B1 (ko) | 2005-07-09 | 2014-01-02 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체 |
| CA2637375A1 (en) | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| CA2637373A1 (en) | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| CN101378740A (zh) | 2006-02-02 | 2009-03-04 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| CN101421255A (zh) * | 2006-02-15 | 2009-04-29 | 艾博特公司 | 新的乙酰辅助a羧化酶（acc）抑制剂及其在糖尿病、肥胖症和代谢综合症中的应用 |
| WO2008035306A1 (en) * | 2006-09-21 | 2008-03-27 | Piramal Life Sciences Limited | 3 -amino- pyridine derivatives for the treatment of metabolic disorders |
| WO2012162463A1 (en) * | 2011-05-25 | 2012-11-29 | Janssen Pharmaceutica Nv | Benzothiazolyl inhibitors of pro-matrix metalloproteinase activation |
| CA2979033A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| CN110996951A (zh) | 2017-04-03 | 2020-04-10 | 科赫罗斯生物科学股份有限公司 | 治疗进行性核上性麻痹的PPARγ激动剂 |
| CN109651208B (zh) * | 2017-10-10 | 2022-01-04 | 中国科学院上海药物研究所 | N-芳基磺酰胺类化合物，其药物组合物及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3632329A1 (de) * | 1986-09-24 | 1988-03-31 | Bayer Ag | Substituierte phenylsulfonamide |
| ES2317688T3 (es) * | 1998-01-29 | 2009-04-16 | Amgen Inc. | Moduladores ppar-gamma. |
| DK1192137T3 (da) * | 1999-06-30 | 2013-11-11 | Amgen Inc | Forbindelser til modulering af PPAR-gamma aktivitet |
-
2001
- 2001-06-27 ES ES01950669T patent/ES2265435T3/es not_active Expired - Lifetime
- 2001-06-27 KR KR1020027017927A patent/KR100771286B1/ko not_active Expired - Lifetime
- 2001-06-27 AU AU2001271637A patent/AU2001271637B2/en not_active Expired
- 2001-06-27 JP JP2002505381A patent/JP4515026B2/ja not_active Expired - Lifetime
- 2001-06-27 SK SK1835-2002A patent/SK288236B6/sk not_active IP Right Cessation
- 2001-06-27 EP EP01950669A patent/EP1296967B1/en not_active Expired - Lifetime
- 2001-06-27 AT AT01950669T patent/ATE327984T1/de active
- 2001-06-27 DK DK01950669T patent/DK1296967T3/da active
- 2001-06-27 DE DE60120163T patent/DE60120163T2/de not_active Expired - Lifetime
- 2001-06-27 CZ CZ20024197A patent/CZ302982B6/cs not_active IP Right Cessation
- 2001-06-27 IL IL15346101A patent/IL153461A0/xx active IP Right Grant
- 2001-06-27 HU HU0301482A patent/HUP0301482A3/hu unknown
- 2001-06-27 WO PCT/US2001/020756 patent/WO2002000633A1/en not_active Ceased
- 2001-06-27 PL PL359996A patent/PL214670B1/pl unknown
- 2001-06-27 MX MXPA02012708A patent/MXPA02012708A/es active IP Right Grant
- 2001-06-27 CN CNB018120172A patent/CN1243741C/zh not_active Expired - Lifetime
- 2001-06-27 PT PT01950669T patent/PT1296967E/pt unknown
- 2001-06-27 EA EA200300078A patent/EA005976B1/ru not_active IP Right Cessation
- 2001-06-27 NZ NZ523229A patent/NZ523229A/en not_active IP Right Cessation
- 2001-06-27 AU AU7163701A patent/AU7163701A/xx active Pending
- 2001-06-27 HK HK03104574.3A patent/HK1052351B/en not_active IP Right Cessation
- 2001-06-27 CA CA2412723A patent/CA2412723C/en not_active Expired - Lifetime
- 2001-06-27 BR BRPI0112115A patent/BRPI0112115B8/pt not_active IP Right Cessation
-
2002
- 2002-12-16 IL IL153461A patent/IL153461A/en unknown
- 2002-12-19 ZA ZA2002/10283A patent/ZA200210283B/en unknown
- 2002-12-20 NO NO20026156A patent/NO325448B1/no not_active IP Right Cessation
-
2006
- 2006-08-07 CY CY20061101099T patent/CY1105126T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1296967B1 (en) | Benzothiazolyl ppar-gamma modulators | |
| US6583157B2 (en) | Quinolinyl and benzothiazolyl modulators | |
| US7968567B2 (en) | Compounds for the modulation of PPARγ activity | |
| US7960408B2 (en) | Quinolinyl and benzothiazolyl modulators | |
| AU2001271637A1 (en) | Quinolinyl and benzothiazolyl ppar-gamma modulators | |
| CA2377309C (en) | Compounds for the modulation of ppar.gamma. activity | |
| US20050250820A1 (en) | Therapeutic modulation of PPARgamma activity | |
| AU779730B2 (en) | Compounds for the modulation of PPARgamma activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE | Patent expired |
Effective date: 20210626 |